Loading…
Employees: 1,033
Size Bliss GVS Pharma (BLISSGVS.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $698M, the 723rd largest of 1,058 India companies the cockpit tracks. Shares closed at ₹614.25 on 6 Nov 2026.
Performance Over six months the shares gained 125.8%, against -6.6% for the median peer and 0.0% for the India market (cap-weighted) — highest of 21 in its peer set.
Growth Revenue grew 20.6% over the last twelve months (peer median +10.2%); the operating margin is 15.1% (peer median 11.1%).
Valuation It trades at 6.6× enterprise value to sales against a peer median of 3.2× (6th most expensive of 18).
Price implies For today's price to make sense, revenue must grow about 37% a year for seven years (Req g). Recent delivered growth is +10%, so the hurdle is +27 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 3.1 points below its cost of capital (12.4% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹10.1B | ₹9.21B | ₹8.02B | ₹7.66B | ₹7.47B |
| Revenue growth | — | +15% | +5% | +2% | — |
| Gross profit | ₹3.74B | ₹3.07B | ₹2.33B | ₹2.49B | ₹2.33B |
| EBITDA | ₹1.87B | ₹1.66B | ₹1.23B | ₹1.49B | ₹1.17B |
| Net income | ₹1.36B | ₹1.29B | ₹843M | ₹755M | ₹709M |
| Free cash flow | n/a | ₹839M | ₹392M | ₹734M | -₹525M |
| Capital expenditure | n/a | ₹568M | ₹763M | ₹283M | ₹938M |
| Total debt | n/a | ₹218M | ₹881M | ₹998M | ₹1.02B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | BLISSGVS.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -9.9% | -5.0% | 8th lowest of 21 |
| 6-month return | +125.8% | -6.6% | highest of 21 |
| Distance from 52-week high | -17.0% | -29.4% | 4th highest of 21 |
| Revenue growth (TTM) | +20.6% | +10.2% | 6th highest of 18 |
| Operating margin | 15.1% | 11.1% | 7th highest of 17 |
| EV / Sales | 6.6× | 3.2× | 6th most expensive of 18 |
| Growth the price implies (Req g, 7 yrs) | 37.0% | 10.3% | 3rd most demanding of 10 |
| Growth delivered (Del g) | +10.1% | +7.9% | 5th highest of 10 |
| Hurdle (Req g minus delivered) | +26.9 pp | +2.5 pp | 4th most demanding of 10 |
| ROIC minus cost of capital | -3.1 pp | -0.3 pp | 8th lowest of 16 |
| EV / EBITDA | 35.2× | 8.2× | 2nd most expensive of 8 |
| Net debt / EBITDA | -1.0× | -1.2× | 4th most indebted of 8 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Bliss GVS Pharma BLISSGVS.NS | India | $698M | +126% | +21% | 15% | 6.6× | 37.0% | +10.1% |
| Philogen PHIL.MI | Italy | $694M | -7% | +295% | 79% | 0.9× | n/a | n/a |
| Sagimet Biosciences SGMT | United States | $693M | +28% | n/a | n/a | n/a | n/a | n/a |
| Beijing Beilu Pharmaceutical 300016.SZ | China | $692M | -16% | +23% | 11% | 3.2× | 10.3% | +7.9% |
| HeiLongJiang ZBD Pharmaceutical 603567.SS | China | $705M | -29% | -82% | n/a | 27.3× | 10.5% | -25.1% |
| Achieve Life Sciences ACHV | United States | $692M | +29% | n/a | n/a | n/a | n/a | n/a |
| Zevra Therapeutics ZVRA | United States | $690M | +4% | +75% | 31% | 3.4× | 0.0% | +51.6% |
| Shandong Wit Dyne Health 000915.SZ | China | $687M | -33% | -36% | 36% | 2.5× | n/a | n/a |
| Hainan Haiyao 000566.SZ | China | $710M | -19% | -18% | -50% | 11.2× | n/a | n/a |
| Jenkem Technology 688356.SS | China | $686M | -23% | +52% | 11% | 10.9× | 41.4% | +11.2% |
| Yabao Pharmaceutical 600351.SS | China | $711M | -3% | -3% | 16% | 1.7× | -7.5% | -2.8% |
| Mochida Pharmaceutical 4534.T | Japan | $683M | -6% | +15% | 9% | 0.7× | n/a | n/a |
| Nuvectis Pharma NVCT | United States | $683M | +79% | n/a | n/a | n/a | n/a | n/a |
| Hubei Biocause Heilen Pharmaceutical 301211.SZ | China | $682M | -5% | +13% | 4% | 6.2× | n/a | n/a |
| Earth 4985.T | Japan | $682M | +6% | +6% | 4% | 0.6× | -2.5% | -1.8% |
| Hangzhou Bio-Sincerity Pharma-Tech 301096.SZ | China | $716M | -24% | +5% | -30% | 8.7× | n/a | n/a |
| Hunan Fangsheng Pharmaceutical 603998.SS | China | $678M | -6% | +10% | 19% | 2.5× | -2.4% | +6.4% |
| Center Laboratories 4123.TWO | Taiwan | $676M | -28% | +4% | 5% | 13.6× | 50.8% | +16.2% |
| Ardelyx ARDX | United States | $724M | -58% | +18% | -8% | 1.5× | n/a | n/a |
| Arbutus Biopharma ABUS | United States | $724M | -16% | +1,079% | 81% | 3.5× | n/a | n/a |
| FDC FDC.NS | India | $672M | +4% | +10% | 14% | 2.5× | 25.9% | +10.3% |